Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Screening fecal calprotectin in diagnosis of IBD is effective

The latest issue of the Clinical Gastroenterology & Hepatology evaluates the effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of IBD in adults and children.

News image

The level of fecal calprotectin can predict the onset of inflammatory bowel disease (IBD) with high accuracy and precision.

Dr Park and colleagues from California, USA evaluated the cost-effectiveness of using measurements of fecal calprotectin to identify adults and children who require endoscopic confirmation of IBD.

The researchers constructed a decision analytic tree to compare the cost-effectiveness of measuring fecal calprotectin before endoscopy examination with that of direct endoscopic evaluation alone.

A second decision analytic tree was constructed to evaluate the cost-effectiveness of fecal calprotectin cutoff levels of 100 μg/g vs 50 μg/g.

Fecal calprotectin screening saved $417 per patient
Clinical Gastroenterology & Hepatology

The team's primary outcome measure was the incremental cost required to avoid 1 false-negative result by using fecal calprotectin level to diagnose new-onset IBD.

In adults, fecal calprotectin screening saved $417 per patient but delayed diagnosis for 2 out of 32 patients with IBD among 100 screened patients.

In children, fecal calprotectin screening saved $300 per patient but delayed diagnosis for 5 out of 61 patients with IBD among 100 screened patients.

The team observed that if endoscopic biopsy analysis remained the standard for diagnosis, direct endoscopic evaluation would cost an additional $18,955 in adults, and $6250 in children to avoid 1 false-negative result from fecal calprotectin screening.
 
Sensitivity analyses showed that cost-effectiveness of fecal calprotectin screening varied with the sensitivity of the test, and the pre-test probability of IBD in adults and children.

The researchers found that pre-test probabilities for IBD of 75% or less in adults, and 65% or less in children made fecal calprotectin screening cost-effective.

However, it was cost-ineffective if the probabilities were 85% or more and 78% or more in adults and children, respectively.

Compared with the fecal calprotectin cutoff level of 100 μg/g, the cutoff level of 50 μg/g cost an additional $55 and $43 for adults and children, respectively.

However, the team noted that it yielded 2 and 6 additional accurate diagnoses of IBD per 100 screened adults and children, respectively.

Dr Park's team concludes, "Screening adults and children to measure fecal levels of calprotectin is effective and cost-effective in identifying those with IBD on a per-case basis when the pre-test probability is ≤75% for adults and ≤65% for children."

"The utility of the test is greater for adults than children."

"Increasing the fecal calprotectin cutoff level to ≥50 μg/g increases diagnostic accuracy without substantially increasing total cost."

Clin Gastroenterol Hepatol 2014: 12(2):  253-262.e2
24 January 2014

Go to top of page Email this page Email this page to a colleague

 25 January 2015

Advanced search
 23 January 2015 
Fecal microbiota transplantation
 23 January 2015 
Liver transplant outcomes
 23 January 2015 
Breath analysis in IBD
 22 January 2015 
NAFLD and NASH with psoriasis
 22 January 2015 
Predicting outcomes in HCV-related advanced liver disease
 22 January 2015 
NASH and lipid improvements
 21 January 2015 
Colon capsule versus CT colonography
 21 January 2015 
Barrett's esophagus screening in the community
 21 January 2015 
Portal vein obstruction
 20 January 2015 
Modulating mucosal damage in Crohn's
 20 January 2015 
Novel techniques for Barrett's screening
 20 January 2015 
Food intolerance
 19 January 2015 
Treatment of fecal incontinence
 19 January 2015 
Hepatic cyst infection
 19 January 2015 
Risk of IBS among relatives
 16 January 2015 
Fecal incontinence
 16 January 2015 
Colorectal cancer screening uptake
 16 January 2015 
NAFLD and NASH in patients with psoriasis
 15 January 2015 
Coffee intake and liver disease
 15 January 2015 
NAFLD in primary care practice
 15 January 2015 
Management of univestigated dyspepsia
 14 January 2015 
Missed colorectal cancers after colonoscopy with polypectomy
 14 January 2015 
Inflixmab response in Crohn's
 14 January 2015 
Statins and liver injury in chronic liver disease
 13 January 2015 
Cytomegalovirus in IBD
 13 January 2015 
Helicobacter-negative gastritis
 13 January 2015 
Hep B vaccine in IBD
 12 January 2015 
Survival in Hep B virus-related hepatocellular carcinoma
 12 January 2015 
Relapse of Crohn's disease after surgery
 12 January 2015 
Late liver metastases of colorectal cancer
 09 January 2015 
Fecal microbiota transplantation for refractory Crohn's
 09 January 2015 
Hypercoagulability after liver resection
 09 January 2015 
Naps and gastroesophageal reflux vs nocturnal sleep
 08 January 2015 
Post-infectious functional dyspepsia
 08 January 2015 
Diagnosis of liver iron overload
 08 January 2015 
Digestive tract damage in Crohn's disease
 07 January 2015 
Early-onset colorectal cancer
 07 January 2015 
SSRIs for noncardiac chest pain
 07 January 2015 
SSRIs and upper GI bleeds
 06 January 2015 
Detection of inflammation in Crohn's
 06 January 2015 
Leptin and early-onset extreme obesity
 06 January 2015 
Goals of IBD treatment
 19 December 2014 
Thiopurine treatment and colectomy in ulcerative colitis
 19 December 2014 
Idiopathic inflammatory demyelinating disease in IBD
 19 December 2014 
Colorectal cancer risk for first-degree relatives
 18 December 2014 
Vitamin D and sustained virologic response in HCV
 18 December 2014 
Factor for treatment in IBS
 18 December 2014 
Assessment of Crohn's disease activity
 17 December 2014 
Remission from hepatic encephalopathy with rifaximin
 17 December 2014 
Colonic adenoma recurrence after endoscopic resection
 17 December 2014 
Non-invasive measures of fatty liver
 16 December 2014 
Diagnostic tool for dysplasia in Barrett's
 16 December 2014 
Screening esophagus during routine US
 16 December 2014 
Therapeutic targets in IBD
 15 December 2014 
Food allergy and food intolerances
 15 December 2014 
Esophageal adenocarcinoma and Barrett's
 15 December 2014 
Outcomes of mildly abnormal liver function tests
 12 December 2014 
Hospital readmission after colorectal resection
 12 December 2014 
Detecting intestingal damage in Crohn's
 12 December 2014 
SSRIs for noncardiac chest pain

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us